Watchlist Price Alert

Ascendis Pharma A/S (ASND)

NASDAQ: ASND · Real-Time Price · USD

177.69

6.89 (4.03%)

At close: Jun 16, 2025, 3:59 PM

177.72

0.02%

After-hours: Jun 16, 2025, 06:41 PM EDT

4.03% (1D)

Bid	165.28
Market Cap	10.73B
Revenue (ttm)	368.7M
Net Income (ttm)	-341.67M
EPS (ttm)	-6.68
PE Ratio (ttm)	-26.6
Forward PE	91.54
Analyst	Buy

Ask	182
Volume	373,705
Avg. Volume (20D)	502,360
Open	171.55
Previous Close	170.80
Day's Range	169.90 - 178.19
52-Week Range	111.09 - 183.00
Beta	0.36

About ASND

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ASND

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ASND stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

2 weeks ago

+7.89%

Ascendis Pharma shares are trading higher after th... Unlock content with Pro Subscription

3 months ago

+8.41%

Ascendis Pharma shares are trading higher after Evercore ISI raised its price target on the stock from $220 to $260.

News

3 weeks ago · accessnewswire.com

Cerrado Gold and Ascendant Resources Announce Completion of Business Combination Transaction

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, ON / ACCESS Newswire / May 20, 2025 / Cerrado Gold Inc. ("Cerrado") (TSXV:CERT)(OTCQX:CRDOF) and Asce...

1 month ago · seekingalpha.com

Ascendis Pharma A/S (ASND) Q1 2025 Earnings Call Transcript

Ascendis Pharma A/S (ASND) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Scott Smith - Executive Vice President and Chief Financial Officer Jan Mikkelsen - President and...

2 months ago · zacks.com

Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?

Here is how Ascendis Pharma A/S (ASND) and Benitec Biopharma Limited (BNTC) have performed compared to their sector so far this year.

2 months ago · seekingalpha.com

Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory

Shares of ASND have fared well during recent market volatility and the downturn in the biotech sector. Setbacks for competitors in PTH (hypoparathyroidism) paves the way for successful Yorvipath launc...

2 months ago · accessnewswire.com

Ascendant Resources Notifies Shareholders Of Upcoming Special Meeting

TORONTO, ON / ACCESS Newswire / April 14, 2025 / Further to its press release on February 3, 2025, Ascendant Resources Inc. (the "Company" or "Ascendant") (TSX:ASND) announces that it has mailed and f...

3 months ago · zacks.com

Ascendis Pharma (ASND) Soars 10.4%: Is Further Upside Left in the Stock?

Ascendis Pharma (ASND) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.